Genetically Engineered Mouse Model (GEMM) Development Services

Genetically engineered mouse models develop tumors in situ, in the animal’s native tissue, driven by defined genetic alterations rather than by implantation of tumor material. The tumor arises where the disease arises in patients, in the presence of a fully intact immune system, and progresses through the stages of initiation, progression, and in many models metastasis. No implanted model reproduces that sequence, because in an implanted model the tumor is already established at the moment the study begins.

Altogen Labs provides GEMM development services for programs where autochthonous tumor initiation and an intact murine immune system are required. Work is conducted in an IACUC-regulated facility. To discuss whether a program justifies a GEMM, request a quote.

What a GEMM provides that an implanted model cannot

Three features distinguish the platform. Tumors initiate from normal tissue, so the earliest stages of transformation and the tissue response to them can be observed, which is a prerequisite for chemoprevention research and for studying early detection markers.

The immune system is intact and has co-evolved with the tumor from initiation, rather than encountering an already established mass. Immune tolerance, exclusion, and editing develop as they do in spontaneous disease, which matters for immuno-oncology questions that depend on how a tumor and immune system reach their equilibrium rather than only on how a therapy disrupts it.

Tumor-stroma interaction develops in native tissue rather than at an implantation site, so the microenvironment is the one the tumor built rather than one it was placed into.

Limitations that determine when to use one

These advantages carry real costs, and a GEMM is the wrong choice for most questions. Breeding and genotyping add lead time before any study can begin, and tumor latency is variable between animals, which means study start is staggered rather than synchronized and cohort assembly takes longer than in an implanted model.

The biology is murine throughout. Human target sequence, epitope, and drug cross-reactivity must be confirmed for the species, and a human-specific biologic cannot be evaluated without a surrogate. Colony maintenance costs are ongoing rather than per study.

The practical consequence is that GEMMs are appropriate for mechanism, initiation, immune-editing, and chemoprevention questions, and inappropriate for routine efficacy screening, which cell line derived xenografts answer faster and at a fraction of the cost. Where the requirement is an intact immune system without the cost of autochthonous initiation, syngeneic models or GEMM-derived allografts are usually the better answer.

Applications

Typical applications include mechanism studies in tumor initiation and progression, immuno-oncology questions dependent on tumor-immune co-evolution, chemoprevention research, target validation in native tissue context, and generation of tumor material for allograft model development.

Applied examples

Immune editing. Tumors arising in an immunocompetent engineered model are compared with the same genetic tumors arising in an immunodeficient background, establishing the contribution of immune pressure to the tumor phenotype that develops.

Early intervention. An agent is administered before tumors are detectable and continued through the latency period, with tumor incidence and time to detection compared against controls, a design impossible in a model where tumors are implanted already formed.

Native stroma. Tumors arising in situ are compared with implanted tumors of the same genotype for stromal composition and drug penetration, addressing whether an implantation site confounds the pharmacology.

Study design and welfare in long-duration models

Study design accounts for staggered tumor onset through enrollment criteria based on tumor detection rather than on a fixed calendar day, with monitoring by imaging or palpation depending on the model. Cohort sizing accounts for variable latency and for the proportion of animals that do not develop tumors within the study window.

All procedures are conducted under active IACUC protocols. Because these are long-duration studies in animals that will develop tumors regardless of treatment, protocols define monitoring frequency, tumor burden limits, and clinical criteria for removal from study, and welfare monitoring is more intensive than in a short implanted study. Model development methodology is not published, and study-specific details are discussed under confidentiality. GLP standards are applied where a study is formally designated as GLP.

Send the genetic alteration of interest, indication, and study objective, or request a quote.